In conclusion, we have shown there was a trend or significant differences in PD‐L1 expression between different histological types in NSCLC, different EGFR status, and different ALK status, and different tumor tissue storage time; a higher survival benefit (TTF or OS) was observed in no PD‐L1 expression than in with PD‐L1 expression in adenocarcinoma, EGFR mutation, and ALK mutation patients. Here, CD274 is linked to adenocarcinoma.